Skip to search formSkip to main contentSkip to account menu

AT7519

Known as: AT 7519, AT-7519, AT7519M 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Purpose: MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs… 
2015
2015
AbstractPurpose ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer… 
Highly Cited
2014
Highly Cited
2014
A vast number of small-molecule ligands, including therapeutic drugs under development and in clinical use, elicit their effects… 
2014
2014
Background:AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs). It shows encouraging anti-cancer… 
Review
2011
Review
2011
BACKGROUND AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs). Based on potent antitumor activity in preclinical… 
2011
2011
Background Eosinophils not only defend the body against parasitic infection but are also involved in pathological inflammatory… 
Highly Cited
2010
Highly Cited
2010
Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent… 
Highly Cited
2010
Highly Cited
2010
AT7519 is a potent inhibitor of several cyclin-dependent kinases and is currently in early phase clinical development. Recently… 
Highly Cited
2009
Highly Cited
2009
Cyclin-dependent kinases (CDK), and their regulatory cyclin partners, play a central role in eukaryotic cell growth, division… 
Highly Cited
2008
Highly Cited
2008
The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient…